Polaryx Therapeutics, Inc. PLYX Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Immunovant, Inc.IMVT

$126K-60.5%

AeroVironmentAVAV

$1.39M+91.7%

Axsome TherapeuticsAXSM

$95K-75.8%

Equity ResidentialEQR

$0—

Rocket Lab USA, Inc.RKLB

$4.74M+127%

Equity Lifestyle PropertiesELS

$70K+14.8%

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Operating cash flow-$2.1M-191%

Market cap$115.64M—

Return on equity-1,209.8%—

Current ratio3.5×—

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Polaryx Therapeutics, Inc. 's payments of stock issuance costs?: Polaryx Therapeutics, Inc. (PLYX) reported payments of stock issuance costs of $6.75K in Q4 2025.